University of Cambridge > > Cambridge Institute Scientists' Society  > Validation & testing of novel therapeutic targets to treat osteosarcoma

Validation & testing of novel therapeutic targets to treat osteosarcoma

Add to your list(s) Download to your calendar using vCal

If you have a question about this talk, please contact eric.rahrmann.

Dear All,

The Cambridge Institute Scientists’ Society (CISS) would like to invite you all to our biannual seminar series on 10 October 2016 at 13:30 in the CRUK CI Lecture Theatre

Our guest lecturer is: Assistant Prof. Branden Moriarity in the Department of Paediatrics, Division of Hematology/Oncology at the University of Minnesota. Branden is an expert in genome engineering with emphasis on animal models of rare paediatric cancers and immunotherapy. It will be a fantastic talk and we hope to see you all there!!

Talk title: Validation & testing of novel therapeutic targets to treat osteosarcoma

Research summary/interests: Pediatric cancer genetics, gene and immunotherapy, genome engineering. Dr. Moriarity’s laboratory is working on studying the genetics of pediatric cancer, including sarcomas and brain tumors, to identify novel therapeutic targets to better treat pediatric cancer patients. The Moriarity lab uses animal models and comparative genomics approaches to identify new candidate cancer genes. Once identified, candidate genes are functionally studied in human cancer and immortalized cell lines using cutting edge technologies, such as targeted nucleases. The primary targeted nucleases used in the Moriarity lab are the CRISPR /Cas9 and Transcriptional Activator-Like Effector (TALEN) systems, which are used to knockout genes, induce targeted sequence changes, activate and/or repress endogenous gene expression.

All welcome to attend.

Kind regards, CISS committee

This talk is part of the Cambridge Institute Scientists' Society series.

Tell a friend about this talk:

This talk is included in these lists:

Note that ex-directory lists are not shown.


© 2006-2024, University of Cambridge. Contact Us | Help and Documentation | Privacy and Publicity